RxDoctor Payments Data

Till Hansen

Endocrinology, Diabetes & Metabolism · Wailuku, HINPI 1720173214

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $421,595 of the $488,148 with a category attached, or 86.4%. 11 manufacturers reported payments, led by Novo Nordisk at 43.9% of the total. Among endocrinology, diabetes & metabolism clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$488,148in general payments, 2019–2025

Across 810 payments — averaging $602.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$214K
  • Lilly USA, LLC$207K
  • AstraZeneca$48K
  • Corcept Therapeutics$15K
  • Johnson & Johnson$3K
  • Amarin Pharma, Inc.$259
  • plus $638 from 5 others

What the payments were for

  • Consulting fees$7,7312%
  • Speaking & faculty fees$421,59586%
  • Travel & lodging$46,74210%
  • Food & beverage$11,7412%
  • Education$3400%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$488,148 in reported general payments places this provider in the 95th percentile of 22 endocrinology, diabetes & metabolism providers in Hawaii.

See all endocrinology, diabetes & metabolism providers in Hawaii

Other endocrinology, diabetes & metabolism in Wailuku

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →